Alzheimer Disease
Conditions
Keywords
Snoezelen, Multi-sensorial care session, Alzheimer's-type neurodegenerative disease, Dementia
Brief summary
The main objective of this study is to evaluate the effect of 3 months of Snoezelen-type multi-sensory care sessions on NeuroPsychiatric Inventory Questionnaire (NPI-Q) scores for patients with Alzheimer's-type neurodegenerative disease.
Detailed description
The secondary objectives of this study are to study the following elements in relationship to the implementation of a Snoezelen-type multi-sensory care strategy for patients with Alzheimer's-type neurodegenerative disease: A. to evaluate the effects on NPI-Q scores at 1 month, 6 months and 12 months . B. evaluate the effects on quality of life (questionnaire QOL-AD) at 0 and 12 months. C. assess changes in the aggressive behavior subsection of the Cohen-Mansfield Agitation Inventory (CMAI) questionnaire over 0, 1, 3, 6 and 12 months. D. assess changes in drug consumption (anxiolytics, antidepressants, hypnotics, neuroleptics)over the study period
Interventions
OTHERMulti-sensory supportive care
The Serre-Cavalier center will implement Snoezelen-type multisensory care sessions for included patients; these care sessions correspond with the patients' daily hygiene/toilette care. The impact of this multisensory strategy will be evaluated using a before-after design.
Sponsors
Centre Hospitalier Universitaire de Nīmes
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The patient's legal representative must have given his/her informed and signed consent (or the patient if he/she is judged competent) * The patient must be insured or beneficiary of a health insurance plan * Alzheimer's-type neurodegenerative pathology * The patient has been living in the participating center for \> 2 months
Exclusion criteria
* The patient's legal representative refuses to sign the consent (or the patient if he/she is judged competent) * It is impossible to correctly inform the patient's legal representative * The patient has already has Snoezelen-therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in NPI-Q scores | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in NPI-Q scores | 1 month |
| Change from baseline in the Quality-of-life-Alzheimer's Disease questionnaire (QOL-AD) | 12 months |
| Change from baseline in the aggressive behavior subsection of the Cohen-Mansfield Agitation Inventory (CMAI) questionnaire | 1 month |
| Change in drug consumption from baseline | 1 month |
Countries
France
Outcome results
None listed